Novel 3-phenylprop-2-ynylamines as inhibitors of mammalian squalene epoxidaseElectronic supplementary information (ESI) available: Proton NMR spectra for the intermediate piperidines 56–60 and acetylenes 63-81 and 85,86. See http://www.rsc.org/suppdata/ob/b2/b209165h/
作者:David L. Musso、Morris J. Clarke、James L. Kelley、G. Evan Boswell、Grace Chen
DOI:10.1039/b209165h
日期:2003.1.30
The synthesis of a novel series of 3-phenylprop-2-ynylamines as selective mammalian squalene epoxidase inhibitors is described. Structure–activity relationship studies led to the discovery of compound 19, 1-[3-(3,5-dichlorophenyl)prop-2-ynyl]-3-methylpiperidine hydrochloride with an IC50 of 2.8 ± 0.6 µM against rat liver squalene epoxidase. Against 23 strains of fungal squalene epoxidase compound 19 was found to be inactive.
Synthesis, Structure and Biological Activities of 2,2-Dichloro-1-(4-ethoxyphenyl)- cyclopropanyl Substituted Piperidin-1-yl Ketone
作者:Na-Bo Sun、Jian-Zhong Jin、Chao Lei、Wei Ke
DOI:10.14233/ajchem.2013.14040
日期:——
Ten new amide-type compounds, which are pyrethroids containing piperidine, are synthesized from 1-(4-ethyoxyphenyl)-2,2-dichlorocyclopropane-1-carboxylic acid and substituted piperidine. Their structures were confirmed by 1H NMR, MS and elemental analysis. The crystal structure of 4a and 4h were determined by X-ray diffraction analysis. The bioassay results indicated that they showed moderate activity.
[EN] NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE<br/>[FR] NOUVEAUX DÉRIVÉS SPIRO D'IMIDAZOLONE AU TITRE D'ANTAGONISTES DE RÉCEPTEURS DE GLUCAGONE, COMPOSITIONS, ET MÉTHODES POUR LEUR UTILISATION
申请人:SCHERING CORP
公开号:WO2011119541A1
公开(公告)日:2011-09-29
The present invention relates to compounds of the general formula (I): wherein ring A, ring B, G, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
[EN] 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS<br/>[FR] PURINES 2,6,7,8-SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HDM2
申请人:MERCK SHARP & DOHME
公开号:WO2014120748A1
公开(公告)日:2014-08-07
The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.